Practical Implementation of the 2013 AHA/ACC Blood Cholesterol Guidelines
- PMID: 25212817
- PMCID: PMC4352137
- DOI: 10.1007/s11936-014-0347-9
Practical Implementation of the 2013 AHA/ACC Blood Cholesterol Guidelines
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United States. Choosing the appropriate patients for whom to initiate statin therapy to reduce the risk of ASCVD is of paramount importance. The new AHA/ACC guidelines on the treatment of cholesterol emphasize a patient-centered approach that shifts away from arbitrary LDL-C goals and recommends targeting statin therapy in patient populations that show ASCVD risk-reduction benefit. In addition, the guidelines emphasize lifestyle modification and the importance of the clinician-patient relationship in discussing ASCVD risk and initiating statin therapy.
Figures
Similar articles
-
Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients.J Am Heart Assoc. 2017 Mar 17;6(3):e004909. doi: 10.1161/JAHA.116.004909. J Am Heart Assoc. 2017. PMID: 28314797 Free PMC article.
-
Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey.Prog Cardiovasc Dis. 2022 Nov-Dec;75:78-82. doi: 10.1016/j.pcad.2022.08.007. Epub 2022 Aug 28. Prog Cardiovasc Dis. 2022. PMID: 36038004
-
Antihyperlipidemic Medication Treatment Patterns and Statin Adherence Among Patients with ASCVD in a Managed Care Plan After Release of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol.J Manag Care Spec Pharm. 2016 Aug;22(8):892-900. doi: 10.18553/jmcp.2016.22.8.892. J Manag Care Spec Pharm. 2016. PMID: 27459651 Free PMC article.
-
Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.Curr Atheroscler Rep. 2017 Jun;19(6):29. doi: 10.1007/s11883-017-0666-x. Curr Atheroscler Rep. 2017. PMID: 28500517 Review.
-
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Am Coll Cardiol. 2019 Jun 25;73(24):3210-3227. doi: 10.1016/j.jacc.2018.11.004. Epub 2018 Nov 10. J Am Coll Cardiol. 2019. PMID: 30423394
References
-
-
Mihaylova B, Emberson J, Blackwell L, Cholesterol Treatment Trialists’ (CTT) Collaborators et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90. One of the key meta-analyses on which the new cholesterol guidelines are based.
-
-
-
Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1(1):CD004816. doi:10.1002/14651858. CD14004816.pub14651855. One of the key meta-analyses on which the new cholesterol guidelines are based.
-
-
-
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults [published online November 12, 2013] Circulation. 2013 doi:10.1161/01.cir.0000437738.63853.7a. The new cholesterol guidelines in detail.
-
-
- Downs J, Claerfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources